Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07179419
Recruiting Observational

Evaluation of the Long-term Therapeutic Effect of High-Intensity Focused Ultrasound (HIFU) Treatment in Patients With Rectal Endometriosis

NCT07179419 · tracked via the Priya Life Science France tracker
Sponsor
EDAP TMS S.A
Phase
Observational
Started
2021-10-10
Last updated
2025-09-17

Condition(s) studied

Endometriosis

Study summary

Evaluate the long-term effects of HIFU treatment for rectal endometriosis.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients who have been treated with HIFU for rectal endometriosis included in study HIFU/F/13.12, study HIFU/F/20.01 (ENDO HIFU R1) or study HIFU/F/21.12 (ENDO HIFU R2) * Agreeing to participate in the study * Patients with internet access so that they can complete the questionnaires electronically. Exclusion Criteria: * Patients deprived of their liberty following a judicial or administrative decision, * Patients under guardianship or conservatorship.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Hopital de la Croix Rousse Lyon France Recruiting

More EDAP TMS S.A. trials in France

Clinical Data Collection of Patients Treated With High Intensity Focused Ultrasound (HIFU) by the Focal One for Their Prostate Cancer. Recruiting
Evaluation of the Efficacy of HIFU Treatment on Rectal Endometriosis Symptoms. Active, not recruiting
Evaluating the Safety and Efficacy of the "HIFU" High-intensity Focused Ultrasound Treatment of Benign Prostatic Hyperplasia; Recruiting

Other trials for the same condition

Educational Program for the Multidisciplinary Support of Patients With Endometriosis Recruiting
National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis Recruiting
Diffusion Endometriosis MRI to Detect and Quantify Symptomatic Neurological Impairment in Pelvic Endometriosis Starting soon
Fusion Ultrasound for Diagnosis and Monitoring of Endometriosis Lesions Active, not recruiting
Clinical and Molecular Study of Endometriosis and Adenomyosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07179419 on ClinicalTrials.gov ↗ ← All trials in France